Efficacy and safety of oral semaglutide in Chinese participants with type 2 diabetes: Subgroup analyses by baseline characteristics in the PIONEER 11 and 12 randomised controlled trials
Authors' conclusion
Oral semaglutide reduces HbA1c and body weight across a range of baseline subgroups in a Chinese population with type 2 diabetes without any unexpected additional safety concerns. These results support the use of oral semaglutide in a broad population in clinical practice.
Study context
- Population
- Chinese participants aged ≥18 years with T2D from the PIONEER 11 and 12 trials390 (PIONEER 11), 1084 (PIONEER 12)
- Comparison
- Once-daily oral semaglutide 3, 7 or 14 mg vs placebo (PIONEER 11) or sitagliptin 100 mg (PIONEER 12)
- Primary endpoint
- Changes from baseline in HbA1c and body weight in subgroups by baseline age, HbA1c, BMI, diabetes duration and gastrointestinal disease
- Follow-up
- Week 26
Primary result
As reported in the abstract
Change in HbA1c and body weight by baseline subgroups
Significant difference in HbA1c change by baseline HbA1c subgroups, with greater reductions in subgroups with higher baseline HbA1c
pint <0.05
Safety
- Most adverse events (AEs) were gastrointestinal-related and mild-to-moderate
Original publication
Efficacy and safety of oral semaglutide in Chinese participants with type 2 diabetes: Subgroup analyses by baseline characteristics in the PIONEER 11 and 12 randomised controlled trials. Diabetes Obes Metab. Published 22 August 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →